4D Molecular Therapeutics, Inc. (FDMT) 8-K Current Report: March 18, 2026
Filed: March 18, 2026
Health Care
Biological Products, (No Diagnostic Substances)4D Molecular Therapeutics, Inc. (FDMT) 8-K current report filed with SEC EDGAR on March 18, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
4D Molecular Therapeutics, Inc. 8-K Mar 18, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Full year 2025 financial results announced, details in press release titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”
- • Press release furnished as Exhibit, key financial and operational updates available there
- • Signals transparency on 2025 performance, guiding investor expectations for upcoming milestones
Get deeper insights on 4D Molecular Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.